4-Tert-Butyl-N-[2-Methyl-3-(6-{[4-(Morpholin-4-Ylcarbonyl)phenyl]amino}-7h-Purin-2-Yl)phenyl]benzamide | 1608120-09-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Tert-Butyl-N-[2-Methyl-3-(6-{[4-(Morpholin-4-Ylcarbonyl)phenyl]amino}-7h-Purin-2-Yl)phenyl]benzamide
• 英文别名: 4-tert-butyl-N-[2-methyl-3-[6-[4-(morpholine-4-carbonyl)anilino]-7H-purin-2-yl]phenyl]benzamide
• CAS: 1608120-09-7
• 化学式: C₃₄H₃₅N₇O₃
• 分子量: 589.697
• InChiKey: IGXJXMLDIIGDNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  44
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  125
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  2,6-二氯-9-(四氢-2H-吡喃-2-基)-9h-嘌呤 在 盐酸 、 potassium phosphate 、 四(三苯基膦)钯 、 potassium tert-butylate 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 水 、 甲苯 为溶剂， 生成 4-Tert-Butyl-N-[2-Methyl-3-(6-{[4-(Morpholin-4-Ylcarbonyl)phenyl]amino}-7h-Purin-2-Yl)phenyl]benzamide
  参考文献：
  名称：

  Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases

  摘要：

  Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivatives 3 & 8 as potent and selective BTK inhibitors. Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compound. Compound 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model. Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket. However, physical and ADME properties leading to low oral exposure hindered further development. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.02.075

文献信息

• Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases
  作者：Qing Shi、Andrew Tebben、Alaric J. Dyckman、Hedy Li、Chunjian Liu、James Lin、Steve Spergel、James R. Burke、Kim W. McIntyre、Gilbert C. Olini、Joann Strnad、Neha Surti、Jodi K. Muckelbauer、Chiehying Chang、Yongmi An、Lin Cheng、Qian Ruan、Katerina Leftheris、Percy H. Carter、Joseph Tino、George V. De Lucca

  DOI：10.1016/j.bmcl.2014.02.075

  日期：2014.5

  Investigation of various heterocyclic core isosteres of imidazopyrazines 1 & 2 yielded purine derivatives 3 & 8 as potent and selective BTK inhibitors. Subsequent SAR studies of the purine series led to the discovery of 20 as a leading compound. Compound 20 is very selective when screened against a panel of 400 kinases and is a potent inhibitor in cellular assays of human B cell function including B-Cell proliferation and CD86 cell surface expression and exhibited in vivo efficacy in a mouse PCA model. Its X-ray co-crystal structure with BTK shows that the high selectivity is gained from filling a BTK specific lipophilic pocket. However, physical and ADME properties leading to low oral exposure hindered further development. (C) 2014 Elsevier Ltd. All rights reserved.